title: Dependence of tumor cell lines and patient-derived tumors on the NAD salvage pathway renders them sensitive to NAMPT inhibition with GNE-618.
abstract: Nicotinamide adenine dinucleotide (NAD) is a critical metabolite that is required for a range of cellular reactions. A key enzyme in the NAD salvage pathway is nicotinamide phosphoribosyl transferase (NAMPT), and here, we describe GNE-618, an NAMPT inhibitor that depletes NAD and induces cell death in vitro and in vivo. While cells proficient for nicotinic acid phosphoribosyl transferase (NAPRT1) can be protected from NAMPT inhibition as they convert nicotinic acid (NA) to NAD independent of the salvage pathway, this protection only occurs if NA is added before NAD depletion. We also demonstrate that tumor cells are unable to generate NAD by de novo synthesis as they lack expression of key enzymes in this pathway, thus providing a mechanistic rationale for the reliance of tumor cells on the NAD salvage pathway. Identifying tumors that are sensitive to NAMPT inhibition is one potential way to enhance the therapeutic effectiveness of an NAMPT inhibitor, and here, we show that NAMPT, but not NAPRT1, mRNA and protein levels inversely correlate with sensitivity to GNE-618 across a panel of 53 non-small cell lung carcinoma cell lines. Finally, we demonstrate that GNE-618 reduced tumor growth in a patient-derived model, which is thought to more closely represent heterogeneous primary patient tumors. Thus, we show that dependence of tumor cells on the NAD salvage pathway renders them sensitive to GNE-618 in vitro and in vivo, and our data support further evaluation of the use of NAMPT mRNA and protein levels as predictors of overall sensitivity.
authors.affiliation: Department of Translational Oncology, Genentech, South San Francisco, CA.
authors.forename: Yang
authors.initials: Y
authors.lastname: Xiao
authors.forename: Kristi
authors.initials: K
authors.lastname: Elkins
authors.forename: Jenni K
authors.initials: JK
authors.lastname: Durieux
authors.forename: Leslie
authors.initials: L
authors.lastname: Lee
authors.forename: Jason
authors.initials: J
authors.lastname: Oeh
authors.forename: Lulu X
authors.initials: LX
authors.lastname: Yang
authors.forename: Xiaorong
authors.initials: X
authors.lastname: Liang
authors.forename: Chris
authors.initials: C
authors.lastname: DelNagro
authors.forename: Jarrod
authors.initials: J
authors.lastname: Tremayne
authors.forename: Mandy
authors.initials: M
authors.lastname: Kwong
authors.forename: Bianca M
authors.initials: BM
authors.lastname: Liederer
authors.forename: Peter K
authors.initials: PK
authors.lastname: Jackson
authors.forename: Lisa D
authors.initials: LD
authors.lastname: Belmont
authors.forename: Deepak
authors.initials: D
authors.lastname: Sampath
authors.forename: Thomas
authors.initials: T
authors.lastname: O'Brien
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy / Q000378:metabolism*; D016923:Cell Death / Q000187:drug effects; D045744:Cell Line, Tumor; D064593:Heterografts; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy / Q000378:metabolism*; D008819:Mice, Nude; D009243:NAD / Q000378:metabolism*; D010430:Pentosyltransferases / Q000037:antagonists & inhibitors* / Q000235:genetics; D011720:Pyrazoles / Q000494:pharmacology* / Q000627:therapeutic use; D013450:Sulfones / Q000494:pharmacology* / Q000627:therapeutic use
chemical_list: D000970:Antineoplastic Agents; C000591154:GNE-618; D011720:Pyrazoles; D013450:Sulfones; D009243:NAD; D010430:Pentosyltransferases; C021864:nicotinate phosphoribosyltransferase